‘Hyundai Motor·Kia’ stock price plunges…Hyundai Bio-Daesung Changto-Itron is strong [종합]

[MHN 문화뉴스 한진리 기자] On February 8th, we look at the characteristic stock.

Apple and Hyundai Motor Company and Kia stopped discussing self-driving electric vehicles.

On the 8th, Hyundai Motor and Kia announced, “We are receiving requests for cooperation in joint development of autonomous electric vehicles from a number of companies, but this has not been decided in an early stage.”

He said, “We are not in consultation with Apple on the development of autonomous vehicles.”

Earlier, in January, a report came out that Apple suggested cooperation with Hyundai Motor Company related to’Apple Car’.

In its official position, Hyundai Motor Company said, “Apple has proposed cooperation for the launch of an Apple car, and related discussions are in progress,” and said, “However, negotiations have not yet been decided in the early stages.” An industry insider said, “Hyundai Motor is one of several companies that Apple has proposed to cooperate with,” and “Apple Car participation is not definitive.”

Since the report, the stock price has risen sharply as individual investors of Hyundai Motor Group stocks rush to buy. Share price increases were highest in the order of Hyundai Wia, Kia Motors, Hyundai Mobis, and Hyundai Motors.

Reports by CNBC, the US economic media, sparked good news. CNBC said that negotiations to manufacture an Apple-branded self-driving electric vehicle at the Kia assembly plant in Georgia, USA, are nearing the final stage.

On the other hand, Bloomberg News, citing sources on the 5th (local time), reported that Apple recently halted discussions with Hyundai Motors and Kia for electric vehicle development, increasing confusion among investors during the weekend break.

At the same time as the market started, Hyundai Group stocks plunged one after another as the announcement of the suspension of the’Apple Car’ negotiations came out.

Hyundai Motor Company fell to the 220,000 won mark during the intraday, but rebounded slightly in the afternoon, closing at 234,000 won, down 6.21% (15,500 won) from the previous day.

Hyundai Wia finished trading at 86,600 won, down 11.90% (11,700 won) compared to the previous day, while Hyundai Mobis closed at 322,000 won, down 8.65% (30,500 won).

In particular, the downtrend of Kia Motors was strong.

Kia Motors fell to the 86,000 won mark during the intraday, showing the biggest drop. The stock price closed at 86,300 won, down 14.98% (15,200 won) from the previous day.

Daesung Changto, who participated as an investor in the movie’Seungriho’ distributed through Netflix, is strong.

‘Seungriho,’ starring Song Joong-ki, Kim Tae-ri, Hae Jin Ha, and Jin Sun-gyu, is Korea’s first space science fiction movie that cost 24 billion won.

It tells the story of the crew of the space garbage scavenger,’Seungri,’ discovering the humanoid robot’Dorothy’ known as a weapon of destruction, and getting involved in a dangerous trade.

Immediately after the release, it was said that Daesung Changto, who participated as an investor, received benefits as it ranked first in the world’s popular Netflix movie rankings and continued to be well received.

Daesung Changto closed the deal at 2,460 won, up 29.82% (565 won) from the previous day.

Founded in 1987, Daesung Changtoo is engaged in investment in small and medium-sized business start-ups and venture companies, as well as the formation and execution of startup investment associations.

In March 2010, the company name was changed to Daesung Investment Co., Ltd., and specialized projects such as parts and materials, energy, environment, ICT industry and cultural contents are underway.

Webcash, Innotherapy, Suzentech, and Carrysoft, which were invested in 2019, were listed on the KOSDAQ, and in 2020, Zencurix was re-listed on the KOSDAQ market.

KR Motors reached the upper limit by soaring to the price limit as soon as the market started.

KR Motors closed the deal at 1,145 won, up 29.82% (263 won) from the previous day.

It is interpreted that the sudden surge was driven by a strong buying trend thanks to the favorable acquisition of KR Motors’ stake in Green Mobility.

On the day, KR Motors announced that “It acquired 50.90% of Green Mobility Co., Ltd. for about 2.2 billion won.” Through the acquisition of the stake, KR Motors has become the largest shareholder in Green Mobility.

Green Mobility is an electric motorcycle/tricycle research institute and manufacturing company. Since its establishment in 2012, it is the first Korean company to be designated as a subsidy provider for electric motorcycles by the Ministry of Environment, taking a leading position in the field of electric vehicle research and production.

Founded in 1917, KR Motors was incorporated into the Kolao Group on March 19, 2014, and is engaged in the motorcycle manufacturing business as its main business.

It possesses 700cc high displacement engine technology through continuous independent technology development, and is the only company in Korea to have full line up from 50 to 700cc. Based on production and technology, it has been marketing in overseas markets with a focus on high displacement, and in the domestic market, it has a market share of about 20% based on its own distribution network.

Meanwhile, the industry’s outlook for this acquisition is positive.

In an interview with a media, the Electric Motorcycle Industry Association said, “It will be an opportunity to strengthen global competitiveness,” saying, “It will be an opportunity to strengthen global competitiveness,” said the two companies that are leading the domestic electric motorcycle business.

Phoebe Pharma, a new stock, has reached the upper limit.

At the same time as the market started, PB Pharma, which had a strong buying trend, ended at 42,600 won, up 29.88% (9,800 won) from the previous day, rising to the price limit at 1 pm.

On the 5th, the first day of listing, Phoebe Pharma started trading at 28,800 won, which is significantly below 32,000 won, and the first day after the weekend closure, Phoebe Pharma reached the upper limit on the 8th, which was the first day.

Established in Singapore in 2015, Phoebe Pharma (official name: Prestige Biopharma) is a pharmaceutical company specializing in antibody drug development, focusing on improving cost competitiveness, the core of biosimilar competitiveness, based on various platform technologies.

We are researching and developing biosimilars and new antibody drugs. Avastin biosimilars are undergoing global phase 3 clinical trials, and Humira biosimilars are preparing to apply for IND approval for phase 1 clinical trials in Australia.

Meanwhile, Prestige Biologics, a subsidiary of Phoebe Pharma, submitted a stock report on the 26th of last month, and is about to be listed on the KOSDAQ in March.

EID and Ytron, which invested in the Russian vaccine’Sputnik V’, have reached the upper limit in harmony.

Earlier, the international medical journal The Lancet published the results of phase 3 clinical trials of the Russian vaccine Sputnik V.

Lancet reported that the immunity efficacy of the Russian vaccine reached 92%, and the immunity effect was 91.8% and safety was also confirmed in a clinical trial involving more than 20,000 elderly people aged 60 or older.

The Russian vaccine is expected to bring immunity to the elderly, which is pointed out as a problem with the AstraZeneca vaccine, which is currently being reviewed for domestic approval, and is drawing attention.

The Russian vaccine’Sputnik V’is produced by the Korean Chorus at 150 million doses of Russian vaccine in Korea. The Russian side is known to have signed a contract with RDIF, the parent company of the Korean Chorus, to increase vaccine production to 300 million times.

EID finished the market at 387 won, up 29.87% (89 won) from the previous day.

On December 8 last year, EID announced that it will invest 10 billion won in the first Sputnik New Technology Investment Association. This is equivalent to 7.25% of the equity capital of 137.9 billion. The company said, “The reason is the expectation of return on investment through investment.”

Founded in 2002, eID is engaged in oil wholesale and OMS, cosmetics manufacturing, sales and export, and innovation (ICBM) business.

Signed a contract for design work and construction to integrate a wireless remote solution to the green algae removal facility of EBISTRADE in Japan, and launched the color cosmetics brand’DRESKIN’ in July 2018, in its own shopping mall and in a number of online distribution channels. On sale

Etron closed the deal at 434 won, up 29.94% (100 won) from the previous day.

Etron also announced on December 14 last year that it would invest 10 billion won in the No. 1 Sputnik New Technology Investment Association, an investment association for new technology projects.

Founded in 1999, Etron specializes in IT-related manufacturing and distribution, including building and manufacturing server and storage systems.

Server and storage account for most of the sales composition. The server and storage industries are expanding into various fields as major products that constitute basic hardware infrastructure for IT services.

On a cumulative basis in the third quarter of last year, it recorded 21.4 billion won in sales and 300 million won in operating profit.

Lee Jae-myung, Governor of Gyeonggi Province, is classified as a related stock.

A warm wind blew in the castle as it climbed to the 1,300 won mark on this day. The stock price ended at 1,220 won, up 9.42% (105 won) from the previous day.

Founded in 1976, Seongan is engaged in manufacturing, processing and sales of textile products, import and export business, and real estate rental business. Textile product manufacturing, sales and import and export business account for more than 90% of sales.

Seongan was known as Governor Lee and Chung-Ang University alumni, and was referred to as the theme week by vice president Park Sang-wan.

Earlier, Governor Lee solidified the system of independent presidential leadership by achieving the first place in the approval rating of the next presidential candidate.

When Gallup Korea asked 1002 people aged 18 or older across the country on the 2nd to 4th,’Who do you think is good as the next president?’ Lee Jae-myung, governor of Gyeonggi Province, ranked first with 27%.

Lee Governor rose 4 percentage points from last month (23%), recording the highest number since the start of the Gallup Korea survey. The preference was remarkable in Incheon and Gyeonggi (41%), men (35%), and 40s (38%).

Together with the Democratic Party leader Lee Nak-yeon, 10% was ranked second, and Prosecutor General Yoon Seok-yeol maintained third place with 9%. Following the National Assembly’s representative Ahn Chul-soo (5%) and independent lawmaker Hong Jun-pyo (2%).

Hyundai Bio has slightly increased.

Hyundai Bio, which has soared from 2 pm to 3 pm, has risen to the 39,000 won mark, near the price limit. After that, it fell slightly and closed at 32,450 won, up 4.51% (1,400 won) from the previous day.

Earlier, on the 2nd, Hyundai Bio reached the upper limit on the announcement that the effect of the COVID-19 treatment will be in full swing.

On the website, Hyundai Bio said, “The animal efficacy test of’CP-COV03′, an oral drug recreated as a drug for COVID-19 by improving the absorption rate of niclosamide in the body, was conducted from the 2nd to the 9th of the same month at the Chonbuk National University Infectious Disease Research Institute. “Do it”.

He added, “The corona 19 effect test was initially scheduled to begin in early January, but it was delayed due to facility sterilization and equipment inspection of the Chonbuk National University’s Infectious Disease Research Institute,” he added.

Established after spun off from Hyundai Electronics in 2000, Hyundai Bio is engaged in manufacturing and sales of bio cosmetics and wool products using’Vitabrid’, a new vitamin C substance for skin.

In addition to the bio-cosmetics business, it is expanding its business to the pharmaceutical field, such as the development of new drugs for improving inflammation after cataract surgery in cooperation with C&Pharm, the largest shareholder, and clinical preparation for new drugs for pancreatic cancer. It is establishing a stable production and sales network through its Vitabrid production plant in Gimcheon, Gyeongsangbuk-do, and overseas subsidiaries in Japan, the United States, and Europe.

---

---

Related Articles

“I hate short selling” Why the anti-short selling leader’Celltrion’ shares fell?

‘Cyworld’ Sky E&M↓ Hyundai Bio-Point Mobile surges, ​Imagine Asia is canceled [종합]

Approval of “Celltrion Corona Treatment”, Bukwang Pharm – Phoebe Pharma – Seongan surge [종합]

EID-NVH Korea-Korea Aerospace skyrocketed, YIK transaction suspended [종합]

Apple Cars and Kia Motors’ final separation?…Who is the’future car’ contender against Tesla?

---

---